Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-5.08%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-5.08%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
Amylyx Pharmaceuticals Inc fundamental performance
Across Amylyx Pharmaceuticals Inc's full reported history, from 2022 to 2025, revenue declined from $ 22M to $ 0.00 and net income went from -$ 198M to -$ 144M. Revenue increased in 25% of the years measured; net income in 50%.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 23.35 | — |
1 Year2025-08-12 | $ 8.20 | 184.76% |
All Time2022-01-07 | $ 18.07 | 29.22% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | All Time2022-01-07 |
|---|---|---|---|
| Price | $ 23.35 | $ 8.20 | $ 18.07 |
| Return | — | 184.76% | 29.22% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 152M | $ 250M |
| 2025 | $ 0.00 | -$ 144M | $ 316M |
| 2024 | $ 87M | -$ 301M | $ 176M |
| 2023 | $ 380M | $ 49M | $ 371M |
| IPO2022 | $ 22M | -$ 198M | $ 346M |
Explore beyond AMLX
You're looking at Amylyx Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
